Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6810226 | Neurobiology of Aging | 2011 | 11 Pages |
Abstract
Soluble forms of amyloid-β peptide (Aβ) are a molecular focus in Alzheimer's disease research. Soluble Aβ dimers (â8 kDa), trimers (â12 kDa), tetramers (â16 kDa) and Aβ*56 (â56 kDa) have shown biological activity. These Aβ molecules have been derived from diverse sources, including chemical synthesis, transfected cells, and mouse and human brain, leading to uncertainty about toxicity and potency. Herein, synthetic Aβ peptide-derived oligomers, cell- and brain-derived low-n oligomers, and Aβ*56, were injected intracerebroventricularly (icv) into rats assayed under the Alternating Lever Cyclic Ratio (ALCR) cognitive assay. Cognitive deficits were detected at 1.3 μM of synthetic Aβ oligomers and at low nanomolar concentrations of cell-secreted Aβ oligomers. Trimers, from transgenic mouse brain (Tg2576), did not cause cognitive impairment at any dose tested, whereas Aβ*56 induced concentration-dependent cognitive impairment at 0.9 and 1.3 μM. Thus, while multiple forms of Aβ have cognition impairing activity, there are significant differences in effective concentration and potency.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Miranda N. Reed, Jacki J. Hofmeister, Lisa Jungbauer, Alfred T. Welzel, Chunjiang Yu, Mathew A. Sherman, Sylvain Lesné, Mary Jo LaDu, Dominic M. Walsh, Karen H. Ashe, James P. Cleary,